Roivant Sciences Ltd. (NASDAQ: ROIV – Get Rating) shares dropped 2.3% during mid-day trading on Tuesday. The company traded as low as $ 4.21 and last traded at $ 4.28. Approximately 4,355 shares were traded during trading, a decline of 100% from the average daily volume of 1,340,506 shares. The stock had previously closed at $ 4.38.
A number of equities analysts have weighed in on the company. The Goldman Sachs Group decreased their price target on Roivant Sciences from $ 15.00 to $ 12.00 and set a “buy” rating for the company in a report on Tuesday, May 24th. Cantor Fitzgerald assumed coverage on Roivant Sciences in a report on Friday, April 29th. They issued an “overweight” rating and a $ 15.00 price target for the company. Finally, SVB Leerink assumed coverage on Roivant Sciences in a report on Monday, May 23rd. They issued an “outperform” rating and a $ 6.00 price target for the company. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Roivant Sciences currently has a consensus rating of “Buy” and a consensus target price of $ 11.86.
The company has a debt-to-equity ratio of 0.09, a quick ratio of 14.23 and a current ratio of 14.23. The company has a 50 day moving average price of $ 3.85 and a 200 day moving average price of $ 5.54.
In other news, CEO Matthew Gline sold 35,386 shares of the stock in a transaction that occurred on Friday, March 25th. The stock was sold at an average price of $ 5.06, for a total transaction of $ 179,053.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Eric Venker sold 80,045 shares of the firm’s stock in a transaction on Friday, March 25th. The stock was sold at an average price of $ 5.06, for a total value of $ 405,027.70. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 480,878 shares of company stock valued at $ 2,011,421.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Eventide Asset Management LLC bought a new position in Roivant Sciences during the fourth quarter worth $ 6,703,000. Two Seas Capital LP acquired a new stake in Roivant Sciences in the fourth quarter worth $ 3,135,000. InterOcean Capital Group LLC acquired a new stake in Roivant Sciences in the fourth quarter worth $ 121,000. Goldman Sachs Group Inc. acquired a new stake in Roivant Sciences in the first quarter worth $ 100,000. Finally, Hsbc Holdings PLC increased its position in Roivant Sciences by 25.4% in the first quarter. Hsbc Holdings PLC now owns 14,684 shares of the company stock worth $ 71,000 after buying an additional 2,978 shares during the period. Hedge funds and other institutional investors own 61.49% of the company stock.
About Roivant Sciences: (NASDAQ: ROIV)
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia.
Further Reading:
Receive News & Ratings for Roivant Sciences Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Roivant Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.
Roivant Sciences Ltd. (NASDAQ: ROIV – Get Rating) shares dropped 2.3% during mid-day trading on Tuesday. The company traded as low as $ 4.21 and last traded at $ 4.28. Approximately 4,355 shares were traded during trading, a decline of 100% from the average daily volume of 1,340,506 shares. The stock had previously closed at $ 4.38.
A number of equities analysts have weighed in on the company. Cantor Fitzgerald assumed coverage on Roivant Sciences in a report on Friday, April 29th. They issued an “overweight” rating and a $ 15.00 price target for the company. The Goldman Sachs Group decreased their price target on Roivant Sciences from $ 15.00 to $ 12.00 and set a “buy” rating for the company in a report on Tuesday, May 24th. Finally, SVB Leerink assumed coverage on Roivant Sciences in a report on Monday, May 23rd. They issued an “outperform” rating and a $ 6.00 price target for the company. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Roivant Sciences currently has a consensus rating of “Buy” and a consensus target price of $ 11.86.
The company has a debt-to-equity ratio of 0.09, a quick ratio of 14.23 and a current ratio of 14.23. The company has a 50 day moving average price of $ 3.85 and a 200 day moving average price of $ 5.54.
In other news, CEO Matthew Gline sold 35,386 shares of the stock in a transaction that occurred on Friday, March 25th. The stock was sold at an average price of $ 5.06, for a total transaction of $ 179,053.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Eric Venker sold 80,045 shares of the firm’s stock in a transaction on Friday, March 25th. The stock was sold at an average price of $ 5.06, for a total value of $ 405,027.70. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 480,878 shares of company stock valued at $ 2,011,421.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Eventide Asset Management LLC bought a new position in Roivant Sciences during the fourth quarter worth $ 6,703,000. Two Seas Capital LP acquired a new stake in Roivant Sciences in the fourth quarter worth $ 3,135,000. InterOcean Capital Group LLC acquired a new stake in Roivant Sciences in the fourth quarter worth $ 121,000. Goldman Sachs Group Inc. acquired a new stake in Roivant Sciences in the first quarter worth $ 100,000. Finally, Hsbc Holdings PLC increased its position in Roivant Sciences by 25.4% in the first quarter. Hsbc Holdings PLC now owns 14,684 shares of the company stock worth $ 71,000 after buying an additional 2,978 shares during the period. Hedge funds and other institutional investors own 61.49% of the company stock.
About Roivant Sciences: (NASDAQ: ROIV)
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia.
Further Reading:
Receive News & Ratings for Roivant Sciences Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Roivant Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.
.